<DOC>
	<DOCNO>NCT01209676</DOCNO>
	<brief_summary>A phase 0 , exploratory study pharmacodynamics single intratumoral dose IMCgp100 , monoclonal T cell receptor anti-CD3 scFv fusion protein , subject advance unresectable melanoma ass safety pharmacodynamic property single intratumoral dos IMCgp100 set advance unresectable melanoma . Six patient enrol complete study approximately 12-15 month .</brief_summary>
	<brief_title>IMCgp100 Advanced Unresectable Melanoma</brief_title>
	<detailed_description>This study test safety effect single dose investigational drug IMCgp100 administer directly metastatic melanoma lesion patient advance metastatic melanoma . IMCgp100 drug make two component . The first T cell receptor design bind specifically tightly protein find high level surface melanoma cancer cell second anti-CD3 fragment meant bind activate T cell . There two stage dose regimen enrol 3 patient . Stage 1 dose 0.00017 mg IMCgp100 Stage 2 dose 0.0017 mg IMCgp100 . Inclusion Criteria : 1 . Histologically confirm dx advance unresectable melanoma require immediate treatment and/or window treatment 2 . Two cutaneous subcutaneous melanoma metastatic lesion 7 15 mm least one dimension amenable subsequent biopsy 3 . Greater equal 18 year age 4 . ECOG PS 0-2 5 . Able provide inform consent willing comply protocol requirement 6 . Female patient must childbearing potential must negative serum pregnancy test 48 hour prior receive investigational drug 7 . Male patient must agree use reliable form birth control throughout study 8 . Must adequate organ system function Exclusion Criteria : 1 . Received chemo , immune , radiation investigational therapy agent within 2 week prior study treatment 2 . Cutaneous metastasis receive prior local therapy 3 . Pregnant breastfeed 4 . History autoimmune disease 5 . Current treatment steroid immunosuppressive med 6 . Active uncontrolled infection 7 . Known HIV infection 8 . Uncontrolled seizures 9 . Known delayed wound heal 10 . On full dose anticoagulation therapy .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Histologically confirm diagnosis melanoma , advance unresectable disease currently require immediate treatment and/or window treatment . 2 . Two cutaneous subcutaneous melanoma metastatic lesion 715 mm least one dimension amenable subsequent biopsy . 3 . Age 18 year 4 . ECOG performance status 02 5 . Able understand provide write informed consent willingness comply protocol requirement ; 6 . Female patient childbearing potential documented medical history ( e.g. , tubal ligation hysterectomy ) , post menopausal minimum 1 year without menses negative serum beta human chorionic gonadotropin ( HGC ) pregnancy test within 48 hour prior receive intratumoral injection agree use acceptable form birth control , define abstinence use intrauterine device ( IUD ) , oral contraceptive , barrier spermicide , hormonal implant throughout study period ; 7 . Male patient must agree use acceptable form birth control throughout study period . 8 . Adequate organ system function evidence laboratory value : Absolute neutrophil count ( ANC ) great equal 1.0 X 109/L Hemoglobin great equal 9 g/dL Platelets great equal 75 X 109/L Total bilirubin less equal 1.5 mg/dL AST ALT less equal 2.5 X ULN ( 2.5 X ULN presence liver metastasis . ) Creatinine le equal 2 mg/dL TSH within normal limit INR/PT PTT less equal 1.3 X ULN 1 . Receive chemotherapy , immunotherapy , radiation therapy , investigational agent ( agent part research protocol approve FDA ) within 2 week prior injection . A minimum 14 day require last therapy injection study . In addition , clinically significant drugrelated toxicity recover grade 1 less ( exclude alopecia ) 2 . Patients without cutaneous subcutaneous metastatic lesion ; 3 . Cutaneous metastasis receive prior local therapy , radiation isolate limb perfusion . 4 . Pregnancy breastfeed 5 . History autoimmune disease ( exclude vitiligo control thyroid disease ) immunodeficiency . 6 . Current treatment steroid ( inhale , topical systemic ) immunosuppressive medication within 2 week injection ; 7 . Active uncontrolled infection ; 8 . Known HIV positivity ; 9 . Uncontrollable seizure ; 10 . Known delayed wound healing ; 11 . Full dose anticoagulation heparin , warfarin , anticoagulant within 2 week injection ; 12 . History acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting , stroke TIA within past 24 week . ; 13 . Known hypersensitivity IMCgp100 component ( ie , Tween ) ; 14 . Class II , III , IV heart failure define New York Heart Association ; 15 . Any psychological , familial , sociological , geographical condition permit compliance protocol . 16 . Any condition investigator opinion would jeopardize compliance protocol ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>melanoma , advance unresectable</keyword>
</DOC>